JRPMS Vol 2, No 3, September 2018, p.75-80
doi: 10.22540/JRPMS-02-075
PDF  
Case Report
A new COL1A1 mutation in a Greek patient with osteogenesis imperfecta: Response to a low-dose protocol of zoledronic acid and two-year follow-up
Michail Sarantis1, Panagoula Kollia2, Stavroula Samara2, Helen Athanasopoulou3, Yolanda Gyftodimou4, Dimitra Lianou5, Evdoxia Mpourazani5, Artemis Doulgeraki3
- 4th Department of Trauma and Orthopaedics, KAT Hospital, Athens, Greece
- Department of Genetics & Biotechnology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece
- Department of Bone and Mineral Metabolism, Institute of Child Health, Athens, Greece
- Department of Clinical Genetics, Institute of Child Health, Athens, Greece
- 1st Department of Pediatrics, “Aghia Sophia” Children’s Hospital, Athens, Greece
Keywords: Osteogenesis imperfecta, Collagen, Zoledronic acid, Mutation
Abstract
Osteogenesis Imperfecta is a severe metabolic bone disorder, mainly caused by mutations of COL1A1 and COL1A2 genes that encode type I procollagen. We report a case of a 7-year-old boy with OI phenotype (recurrent, low-energy fractures, blue sclerae), whose DNA analysis revealed a new mutation of the COL1A1 gene. Herein, his two-year follow-up and his response to current treatment is described (low-dose protocol of zoledronic acid). Also, an insight is given on his metabolic bone profile, unfolding the biochemical response of bone turnover to this bisphosphonate.